On December 13, 2018, the Food and Drug Administration (FDA) announced withdrawal of a controversial proposed rule, first announced in 2013, that would have permitted generic drug companies to make unilateral changes to their product labeling. The decision marked a major victory for WLF, which repeatedly urged FDA to abandon the rule. WLF argued that alternative procedures could ensure that new safety information about FDA-approved drugs reaches doctors and consumers much more quickly than under the proposed rule. WLF argued that the chief result of FDA’s proposal would be consumer confusion, brought on because different versions of the same drug would bear conflicting safety warnings. WLF charged that the proposed rule’s only purpose was to placate the plaintiffs’ bar. Lawyers supported the rule because it would have facilitated the filing of lawsuits against generic drug manufacturers. If they are permitted to change their labels unilaterally, they can be sued for failing to do so.